Buchumschlag

Editorial: Enriching our understanding of MASLD through representation of under‐reported populations

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Niharika Samala, Eduardo Vilar‐Gomez
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
von: Eduardo Vilar‐Gomez, et al.
Veröffentlicht: (2025)

Editorial: Cardiometabolic criteria matters inMASLD
von: Margaret L. P. Teng, et al.
Veröffentlicht: (2024)

Editorial: Hyperferritinaemia—An Ironclad Biomarker for the Prognostication of MASLD?
von: Mark C. C. Cheah, et al.
Veröffentlicht: (2025)

Editorial: NAFLD, NAFLD, or MASLD: what's in a name?
von: Maryam Zafer, et al.
Veröffentlicht: (2024)

Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!
von: Hannah Mohr, et al.
Veröffentlicht: (2025)

Editorial: Accelerometers to Quantify Physical Activity in MASLD—Impact on Clinical Outcomes
von: Vincent L. Chen
Veröffentlicht: (2025)

Editorial: Refining the Natural History of MASLD by Imaging‐Based Markers: The GOLDMINE Study
von: Federico Perna, et al.
Veröffentlicht: (2026)

Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification
von: Takefumi Kimura
Veröffentlicht: (2025)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
von: Mary Yue Wang, et al.
Veröffentlicht: (2025)

Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability?
von: Joshua Reid, et al.
Veröffentlicht: (2024)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
von: Jiru Li, et al.
Veröffentlicht: (2025)

Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD —Insights From a National Analysis. Authors' Reply
von: Donghee Kim, et al.
Veröffentlicht: (2025)

Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply
von: Chia‐Chih Kuo, et al.
Veröffentlicht: (2025)

Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography ( GOLDMINE ): A Multi‐Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes
von: Suzanne Sharpton, et al.
Veröffentlicht: (2026)

Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability? Authors' reply
von: Jessica A. Fitzpatrick, et al.
Veröffentlicht: (2024)

Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
von: Wah‐Kheong Chan, et al.
Veröffentlicht: (2024)

Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof‐Of‐Concept Study
von: R. Sinha, et al.
Veröffentlicht: (2025)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
von: Hassan Javed, et al.
Veröffentlicht: (2025)

A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
von: Maral Amangurbanova, et al.
Veröffentlicht: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
von: Mohamed El‐Kassas, et al.
Veröffentlicht: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
von: C. C. Mark Cheah, et al.
Veröffentlicht: (2025)

Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
von: Maryam Zafer, et al.
Veröffentlicht: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
von: Qiang Hu, et al.
Veröffentlicht: (2024)

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
von: Darren Jun Hao Tan, et al.
Veröffentlicht: (2024)

Letter: A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
von: Xiaojuan Liu, et al.
Veröffentlicht: (2025)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
von: Stuart McPherson, et al.
Veröffentlicht: (2024)

The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic Solutions
von: Carlos José Pirola, et al.
Veröffentlicht: (2025)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis— Time to change our targets?
von: Guilherme Grossi Lopes Cançado
Veröffentlicht: (2024)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
von: Yewan Park, et al.
Veröffentlicht: (2024)

Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time‐Restricted Feeding in MASLD Management—Authors' Reply
von: Sofia Tsitsou, et al.
Veröffentlicht: (2025)

MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
von: Daniela S. Allende, et al.
Veröffentlicht: (2024)

Lubiprostone Reduces Fat Content on MRI‐PDFF in Patients With MASLD: A 48‐Week Randomised Controlled Trial
von: Mohamed El‐Kassas, et al.
Veröffentlicht: (2025)

Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management
von: Jakob B. Seidelin
Veröffentlicht: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
von: C. M. Fernández‐Rodríguez, et al.
Veröffentlicht: (2024)

Prevalence and prognosis of patients with MASLD ‐related cirrhosis after an ICU hospitalization in France: A single‐centre prospective study
von: Philippe Sultanik, et al.
Veröffentlicht: (2024)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
von: Wenjun Meng, et al.
Veröffentlicht: (2024)

Letter: MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
von: Junbin Yan, et al.
Veröffentlicht: (2024)

The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET‐NASH
von: Brent A. Neuschwander‐Tetri, et al.
Veröffentlicht: (2025)

Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study
von: Federica Tavaglione, et al.
Veröffentlicht: (2025)